
    
      This is an enriched enrollment, randomized withdrawal study with an open label,
      dose-titration period followed by a randomized, double-blind, placebo-controlled treatment
      period of 12 weeks. During the double-blind treatment period, this study will evaluate the
      effectiveness of buprenorphine HCl buccal film versus placebo buccal film in treating CLBP in
      subjects.

      Buprenorphine HCl buccal film is an oral transmucosal form of the opioid analgesic,
      buprenorphine hydrochloride, intended for application to the buccal mucosa. Buprenorphine is
      a synthetic opioid that is classified as a partial Âµ-receptor agonist and a Schedule III
      controlled substance in the United States.
    
  